Carisma Therapeutics, Inc.

NasdaqGM:CARM Rapporto sulle azioni

Cap. di mercato: US$35.4m

Carisma Therapeutics Crescita futura

Future criteri di controllo 0/6

Si prevede che i ricavi e gli utili di Carisma Therapeutics diminuiranno rispettivamente del 48.7% e 9.4% all'anno, mentre si prevede che l'EPS crescerà del 26.7% all'anno.

Informazioni chiave

-9.4%

Tasso di crescita degli utili

26.7%

Tasso di crescita dell'EPS

Biotechs crescita degli utili28.4%
Tasso di crescita dei ricavi-48.7%
Rendimento futuro del capitale proprion/a
Copertura analitica

Low

Ultimo aggiornamento18 Nov 2024

Aggiornamenti recenti sulla crescita futura

US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results

May 12
US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results

Recent updates

Companies Like Carisma Therapeutics (NASDAQ:CARM) Could Be Quite Risky

Sep 02
Companies Like Carisma Therapeutics (NASDAQ:CARM) Could Be Quite Risky

US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results

May 12
US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results

Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 26%

Apr 19
Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 26%

We're A Little Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Rate

Mar 26
We're A Little Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Rate

Lacklustre Performance Is Driving Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 26% Price Drop

Jan 21
Lacklustre Performance Is Driving Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 26% Price Drop

The Market Doesn't Like What It Sees From Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Revenues Yet As Shares Tumble 27%

Dec 07
The Market Doesn't Like What It Sees From Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Revenues Yet As Shares Tumble 27%

Analyst Forecasts Just Became More Bearish On Carisma Therapeutics, Inc. (NASDAQ:CARM)

Nov 12
Analyst Forecasts Just Became More Bearish On Carisma Therapeutics, Inc. (NASDAQ:CARM)

Here's Why We're Watching Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation

Oct 05
Here's Why We're Watching Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation

We're Hopeful That Carisma Therapeutics (NASDAQ:CARM) Will Use Its Cash Wisely

Jun 15
We're Hopeful That Carisma Therapeutics (NASDAQ:CARM) Will Use Its Cash Wisely

Previsioni di crescita degli utili e dei ricavi

NasdaqGM:CARM - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/202610-71-65-642
12/31/202518-60-56-554
12/31/202421-54-63-633
9/30/202420-64-68-68N/A
6/30/202421-73-77-76N/A
3/31/202415-81-79-78N/A
12/31/202315-87-82-81N/A
9/30/202314-83-83-82N/A
6/30/202313-80-73-70N/A
3/31/202312-75-69-65N/A
12/31/202210-61-10-5N/A
9/30/20226-57-23N/A
6/30/20224-49-12N/A
3/31/20221-4347N/A
12/31/2021N/A-41-39-37N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che CARM rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che CARM rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che CARM rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che i ricavi di CARM diminuiranno nei prossimi 3 anni ( -48.7% all'anno).

Ricavi ad alta crescita: Si prevede che i ricavi di CARM diminuiranno nei prossimi 3 anni ( -48.7% all'anno).


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di CARM è previsto essere elevato tra 3 anni


Scoprire le aziende in crescita